Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the healthcare sector on Friday, sending the drugmaker's stock price soaring while ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

The US has also ordered 3.1 million doses of molnupiravir for around $2.2 billion. Merck – which is developing the drug with Ridgeback Biotherapeutics – is one step ahead for a regulatory ...

Merck MRK reported fourth-quarter 2024 adjusted ... with $149 million in the previous quarter. Sales of Lagevrio (molnupiravir) declined 37% to $121 million in the quarter. The segment generated ...

Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...

Davis, chairman and chief executive officer, Merck. "We’re continuing to progress our pipeline, advance key clinical programs and augment our pipeline through promising business development.

(1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue ...

Davis, chairman and chief executive officer, Merck. "We’re continuing to progress our pipeline, advance key clinical programs and augment our pipeline through promising business development. Our ...

Merck has changed since its 2021 spin-off of women's health and biosimilar products in Organon. So far, some of the consequently lost revenues have been compensated by the pandemic-boosted sales of ...

He says, if confirmed, he can still earn referral fees from a firm suing Merck. In 2020, as a pandemic raged across the globe, Robert F. Kennedy Jr. took to social media to appeal to his hundreds ...

Merck MRK will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $15.56 billion and $1.72 per ...

Robert F. Kennedy Jr. is not qualified to be health and human services secretary for many reasons, chief among them being his years-long unscientific campaign against essential vaccines.